Global Digital Bioinformatics Market Size (2024 – 2030)

As of 2022, the Global Digital Bioinformatics Market held a valuation of USD 7.76 billion, with projections indicating growth to reach a market size of USD 20.65 billion by the year 2030. Over the forecast period spanning 2024 to 2030, a Compound Annual Growth Rate (CAGR) of 15% is anticipated.

Industry Overview

Digital bioinformatics stands at the intersection of biology and information technology, amalgamating biological data with tools for storage, dissemination, and analysis. This integration serves diverse scientific sectors, particularly within biomedicine. Within the market, bioinformatics software and tools function as comprehensive solutions offering algorithms and statistical methodologies for robust data analysis. These tools play pivotal roles in managing and analyzing data for applications such as next-generation sequencing, genomic and proteomic structuring, as well as three-dimensional drug design modeling. Available bioinformatics tools include homology and similarity tools, protein functional and analytical tools, sequence analysis tools, and a range of miscellaneous tools. The market's trajectory is set to be influenced by heightened Research and Development (R&D) endeavors within the proteomics and genomics sector, along with other related '–omics' fields, in response to escalating demand.

The market for bioinformatics experiences impetus from several key factors such as the escalating demand for personalized medicine, burgeoning research activities in molecular biology and drug discovery, adoption of blockchain technology and cloud computing, an expanding role of Artificial Intelligence (AI) in bioinformatics and healthcare, as well as notable public and private investments. However, constraints pertaining to interoperability, multiplatform capabilities, and potential malpractice are poised to moderate market expansion.

The burgeoning demand for infant nutrition products, attributed to evolving lifestyles and a rising population of working mothers globally, propels the bioinformatics industry forward. The World Health Organization (WHO) reports that only 38% of newborns worldwide are exclusively breastfed, underscoring the market's potential for growth. Additionally, heightened consumer awareness regarding the nutritional benefits of bioinformatics products further augments market progression. The market also finds traction among athletes due to the health benefits offered, such as bolstering the immune system and aiding in muscle maintenance and performance. However, stringent government regulations governing supplement composition and the high costs associated with R&D pose challenges to the industry's growth.

Impact of COVID-19 on the Industry

The COVID-19 pandemic has underscored the substantial potential of bioinformatics in providing critical support to various scientific endeavors. During the pandemic, a primary focus for countries worldwide has been to explore strategies to contain the spread of the virus. Next-generation sequencing has been instrumental in examining SARS-CoV-2 genomes, offering foundational insights into the virus. Bioinformatics pipelines, alongside databases concerning biological and host-virus interactions, serve as indispensable tools in the computation and comprehension of SARS-CoV-2. Consequently, numerous studies are underway, facilitated by evolving bioinformatics skills, to gain a deeper understanding of the virus's genetic composition. Within this context, the outsourcing of bioinformatics has witnessed an upsurge during the pandemic, enabling scientists to unravel various mysteries surrounding SARS-CoV-2, ranging from its identification to its mechanisms of action and transmission.

Market Drivers

The burgeoning funding, both from private and public sectors, directed towards bioinformatics innovations is set to propel market growth.

Governments and corporate entities worldwide are increasingly recognizing the significance of bioinformatics, resulting in substantial investments. These investments have predominantly manifested in advancements in data and technology within bioinformatics services, thereby enhancing their efficacy. For instance, in 2016, the European Molecular Biology Laboratory (EMBL), an intergovernmental organization and a trailblazer in bioinformatics, received funding from various entities such as the Biotechnology and Biological Sciences Research Council, British Heart Foundation, Cancer Research UK, European Commission, European Molecular Biology Organization, European Research Council, National Institutes of Health Foundation, Bill & Melinda Gates Foundation, and the Human Frontier Science Program.

Moreover, several governments are embarking on national population sequencing studies to deepen the understanding of the interplay between genetics and diseases. Government institutions are sequencing the genomes of millions of citizens to foster research and unearth improved diagnostic and therapeutic approaches for conditions such as cancer and rare disorders. Consequently, the demand for bioinformatics products and services is anticipated to witness an upswing, driven by these extensive sequencing endeavors.

Emerging markets present lucrative opportunities, poised to bolster consumer demand for the digital bioinformatics market.

Countries such as India, China, Brazil, Russia, Taiwan, and South Korea hold significant growth potential for major bioinformatics firms. In the forthcoming years, sectors such as genomics, metabolomics (including chromatography, mass spectrometry, and NMR devices), precision medicine, and drug discovery are poised to benefit from the growing importance of these emerging economies in terms of R&D and investments from global entities. Additionally, the Asia Pacific region boasts more adaptable and business-friendly regulatory frameworks, owing to less stringent laws and data requirements. Consequently, manufacturers are expected to intensify their focus on emerging markets as competition within developed nations escalates.

Market Restraints

The market for digital bioinformatics faces constraints due to the high costs associated with equipment.

The advent of powerful Next-Generation Sequencing (NGS) technologies has spurred demand for user-friendly bioinformatics tools that offer rapid and accurate results. However, many experimental research scientists lack the extensive bioinformatics expertise required by numerous applications. Hence, the availability of user-friendly tools is imperative for effective utilization of bioinformatics platforms. Genomics instruments, laden with intricate features and functionalities, entail substantial costs ranging from USD 10–20 million. Given the necessity for multiple genomic instruments within pharmaceutical enterprises and research institutions, significant financial investments are requisite. Consequently, smaller pharmaceutical entities and research facilities often find it economically unfeasible to acquire such instruments.

Moreover, concerns surrounding the privacy of patients' data pose a challenge to the digital bioinformatics market.

The rapid advancements in NGS technology have led to a vast accumulation of biological data, concurrent with the proliferation of NGS applications. Genome analysis yields a trove of information necessitating thorough data analysis. Consequently, the residual data following bioinformatics analysis holds immense value and potential for reuse. Present methodologies often fall short in effectively addressing the complexities of bioinformatics data management.

Global Digital Bioinformatics Market- By Product and Services Type

• Products
• Sequencing Platforms
• Knowledge Management Tools
• Bioinformatics Software
• Services
• Data Analysis
• Sequencing
• Database integration
• Others

The digital bioinformatics sector is segmented into three product types: sequencing platforms, knowledge management tools, and bioinformatics software. There are two classifications for knowledge management tools: generalized and specialized tools. Concerning services, the digital bioinformatics market is further categorized into data analysis, sequencing, database integration, and other services.

Global Digital Bioinformatics Market- By Application

• Preventive Medicine
• Molecular Medicine
• Genomics
• Drug Development
• Transcriptomics
• Others

The bioinformatics sector's applications include preventive medicine, molecular medicine, genomics, drug development, transcriptomics, and other specialized areas. Transcriptomics is expected to show the most significant growth due to the rising demand for companion diagnostics and personalized therapeutics. Various fields such as preventive medicine, molecular medicine, gene therapy, drug development, and others extensively utilize bioinformatics. Additionally, there are applications in microbe forensic analysis, genetic research on antibiotic resistance, and veterinary science. As of 2021, the molecular medicine segment accounted for the largest market share, with the drug development segment projected to experience the fastest growth between 2024 and 2030.

Global Digital Bioinformatics Market- By End-User

• Medical Biotechnology
• Academics
• Animal Biotechnology
• Agricultural Biotechnology
• Environmental Biotechnology
• Forensic Biotechnology

The bioinformatics sector serves various end-users including medical biotechnology, academics, animal biotechnology, agricultural biotechnology, environmental biotechnology, and forensic biotechnology. Among these, the medical biotechnology market is expected to be the largest end-user for the digital bioinformatics industry.

Global Digital Bioinformatics Market- By Geography & Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

The global digital bioinformatics market is geographically divided into five regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. In 2021, North America led the global bioinformatics market, closely followed by Europe. The growth of the bioinformatics market in North America and Europe can be attributed to factors such as advanced technology availability, well-established regulatory frameworks, rapid adoption of new technologies, and significant company investments in research and development. The Asia-Pacific region also shows promise as a lucrative sector for bioinformatics, driven by government initiatives to enhance biotechnology research and development, increased funding, growing awareness of bioinformatics, and rising literacy rates in the region.

Global Digital Bioinformatics Market- By Companies

1. Thermo Fisher Scientific
2. Illumina
3. Agilent Technologies
4. QIAGEN
5. BGI
6. Wuxi Next code
7. Eurofins Scientific
8. Waters Corporation
9. Sophia Genetics
10. Partek

RECENT NOTABLE DEVELOPMENTS IN THE GLOBAL DIGITAL BIOINFORMATICS MARKET:

• Product Launch: - Agilent Technologies, Inc. introduced SureSelect for human exome analysis in March 2021.
• Business Partnership: - BGI expanded its collaboration with Brunei's Ministry of Health in January 2021, encompassing reproductive health, personalized drug counseling, early cancer screening, and the detection of unknown diseases using BGI's advanced sequencing technology.
• Business Partnership: - Charles River Laboratories, Inc. established a partnership with Fios Genomics in January 2020 to leverage the company's expertise in bioinformatics, statistics, and biology.